NICE Turns Attention To Roche's Perjeta After Finally Passing Kadcyla For Breast Cancer

 
• By Sten Stovall
  
Benefit & Cost
NICE finally gave the thumbs up to Roche's Kadcyla for breast cancer
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from Market Access